Search results for "Lisp"

showing 10 items of 87 documents

Potential Solar Radiation as a Driver for Bark Beetle Infestation on a Landscape Scale

2019

In recent decades, Norway spruce (Picea abies L. Karst.) forests of the High Tatra Mountains have suffered unprecedented tree mortality caused by European spruce bark beetle (Ips typographus L.). Analysis of the spatiotemporal pattern of bark beetle outbreaks across the landscape in consecutive years can provide new insights into the population dynamics of tree-killing insects. A bark beetle outbreak occurred in the High Tatra Mountains after a storm damaged more than 10,000 ha of forests in 2004. We combined yearly Landsat-derived bark beetle infestation spots from 2006 to 2014 and meteorological data to identify the susceptibility of forest stands to beetle infestation. We found that digi…

0106 biological sciencesBark beetle010504 meteorology & atmospheric sciencessolar radiationPopulationkirjanpainaja (kaarnakuoriaiset)<i>Ips typographus</i>medicine.disease_cause010603 evolutionary biology01 natural sciencesIps typographustuhohyönteisetInfestationmedicineSolar radiationeducationauringonsäteily0105 earth and related environmental scienceseducation.field_of_studyTatravuoristobiologyintegumentary systemNational parkPicea abiesHigh Tatra MountainsOutbreakNational parknational parkForestryStormForestryPicea abieslcsh:QK900-989biology.organism_classificationpopulaatiodynamiikkakansallispuistotvisual_artlcsh:Plant ecologyvisual_art.visual_art_mediumBark<i>Picea abies</i>metsäkuusiForests
researchProduct

Analysis of nucleophosmin–anaplastic lymphoma kinase (NPM‐ALK)‐reactive CD8+ T cell responses in children with NPM‐ALK+ anaplastic large cell lymphoma

2016

Summary Cellular immune responses against the oncoantigen anaplastic lymphoma kinase (ALK) in patients with ALK-positive anaplastic large cell lymphoma (ALCL) have been detected using peptide-based approaches in individuals preselected for human leucocyte antigen (HLA)-A*02:01. In this study, we aimed to evaluate nucleophosmin (NPM)-ALK-specific CD8+ T cell responses in ALCL patients ensuring endogenous peptide processing of ALK antigens and avoiding HLA preselection. We also examined the HLA class I restriction of ALK-specific CD8+ T cells. Autologous dendritic cells (DCs) transfected with in-vitro-transcribed RNA (IVT-RNA) encoding NPM–ALK were used as antigen-presenting cells for T cell …

0301 basic medicineAdolescentT cellImmunologyHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesLymphocyte ActivationAntibodiesCell Line03 medical and health sciences0302 clinical medicineAntigenAntigens NeoplasmT-Lymphocyte Subsetshemic and lymphatic diseasesmedicineImmunology and AllergyAnaplastic lymphoma kinaseCytotoxic T cellAnimalsHumansChildAnaplastic large-cell lymphomaAllelesintegumentary systemELISPOTHistocompatibility Antigens Class IInfantOriginal ArticlesProtein-Tyrosine Kinasesmedicine.disease030104 developmental biologymedicine.anatomical_structureChild PreschoolImmunologyCancer researchLymphoma Large-Cell AnaplasticCD8030215 immunology
researchProduct

2021

Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality following hematopoietic stem cell transplantation (HSCT). Measuring CMV-specific cellular immunity may improve the risk stratification and management of patients. IFN-γ ELISpot assays, based on the stimulation of peripheral blood mononuclear cells with CMV pp65 and IE-1 proteins or peptides, have been validated in clinical settings. However, it remains unclear to which extend the T-cell response to synthetic peptides reflect that mediated by full-length proteins processed by antigen-presenting cells. We compared the stimulating ability of pp65 and IE-1 proteins and corresponding overlapping peptides in 16 HSCT recip…

0301 basic medicineCellular immunityAntigen processingbusiness.industryELISPOTmedicine.medical_treatmentClinical BiochemistryCongenital cytomegalovirus infectionvirus diseasesImmunosuppressionHematopoietic stem cell transplantationmedicine.diseasePeripheral blood mononuclear cell03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisImmunologyMedicinebusinessCD8Diagnostics
researchProduct

Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome

2016

Cancer accumulates 10s to 1000s of genomic mutations of which a fraction is immunogenic and may serve as an Achilles' heel of tumor cells. Mutation-specific T cells can recognize these antigens and destroy malignant cells. Strategies to immunotherapeutically address individual tumor mutations employing peptide or mRNA based vaccines are now actively investigated in mice and humans. An important step of determining the therapeutic potential of a mutanome vaccine is the detection of mutation reactive T-cell responses. In this chapter we provide protocols to identify and subtype mutation specific T cells in mice based on IFN-γ ELISpot and flow cytometry.

0301 basic medicineMutationmedicine.diagnostic_testELISPOTmedicine.medical_treatmentT cellCancerBiologymedicine.disease_causemedicine.diseaseSubtypingFlow cytometry03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureCancer immunotherapyAntigen030220 oncology & carcinogenesisImmunologymedicine
researchProduct

2021

BackgroundMultiple synergistic combination approaches with cancer drugs are developed to overcome primary resistance to immunotherapy; however, the mechanistic rationale to combine chemoradiotherapy (CRT) with immune checkpoint inhibitors remains elusive.MethodsThis study described the immunological landscape of tumor microenvironment (TME) exposed to CRT. Tumor samples from patients with rectal cancer (n=43) treated with neoadjuvant CRT or radiotherapy were analyzed by nanostring and immunohistochemistry. Studies in mice were performed using three syngeneic tumors (TC1, CT26 and MC38). Tumor-bearing mice were treated either with platinum-based CRT, radiotherapy or chemotherapy. Anti-CTLA-4…

0301 basic medicinePharmacologyCancer ResearchTumor microenvironmentbusiness.industryELISPOTmedicine.medical_treatmentImmunologyImmunotherapyAcquired immune system03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemOncology030220 oncology & carcinogenesismedicineCancer researchMolecular MedicineImmunology and AllergyCytotoxic T cellbusinessCD8ChemoradiotherapyJournal for ImmunoTherapy of Cancer
researchProduct

Generation of TCR-engineered reference cell samples to control T-cell assay performance

2020

In vitro cellular assays analyzing antigen-specific T cells are characterized by their high complexity and require controlled conditions to lower experimental variations. Without standard cellular reagents, it is difficult to compare results over time and across institutions. To overcome this problem, a simple and robust technology was developed to generate TCR-engineered reference samples (TERS) containing defined numbers of antigen-specific T cells. Utilization of TERS enables performance control of three main T-cell assays: MHC-peptide multimer staining, IFN-gamma ELISpot and cytokine flow cytometry. TERS continuously deliver stable results and can be stored for longer periods of time. H…

0303 health sciencesChemistryElectroporationELISPOTT cell030303 biophysicsT-cell receptorfood and beveragesReference cellPerformance control03 medical and health sciencesmedicine.anatomical_structureHigh complexitymedicineCytokine flow cytometryBiomedical engineering
researchProduct

An Immunogenic Peptide Derived from NM23-H2 Is Expressed on Bcr/abl+ Cells.

2006

Abstract Objective: Most tumors express antigens which, when presented by MHC molecules, can be recognized by cytotoxic T-lymphocytes. These tumor-associated-antigens (TAA) are considered to be key determinants in the graft-versus-tumor effect after allogeneic hematopoietic cell transplantation (HCT) and are therefore potential candidates for tumor vaccination. Unfortunately only small numbers of TAA have been isolated to date. In this project we looked for immunogenic peptides presented by bcr/abl+ cells of an HLA-A32 CML patient. Methods: Leukemia-specific mixed lymphocyte leukemia cell cultures (MLLC) were generated by co-culturing irradiated bcr/abl+ cells from the patient with peripher…

ABLELISPOTLymphocyteImmunologybreakpoint cluster regionCell BiologyHematologyBiologyMajor histocompatibility complexBiochemistryMolecular biologymedicine.anatomical_structureAntigenhemic and lymphatic diseasesmedicinebiology.proteinCytotoxic T cellK562 cellsBlood
researchProduct

Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes.

2005

The aim of the present study was to investigate postprandial microvascular blood flow following a standardized test meal in nondiabetic subjects and in patients with Type 1 diabetes after regular insulin or insulin lispro. In this open-label, randomised cross-over study, 20 nondiabetic participants and 20 patients with Type 1 diabetes were enrolled. To valuate the postprandial time course of skin microvascular blood flow, laser Doppler flux (LDF) readings were obtained at baseline and every 30 min following a standardized test meal. Furthermore, the microvascular response to acetylcholine (Ach) was measured, and blood was collected for the measurement of serum insulin and blood glucose leve…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismArbitrary unitmedicine.medical_treatmentEndocrinologyReference ValuesDiabetes mellitusInternal medicineInternal MedicinemedicineInsulin lisproHumansHypoglycemic AgentsInsulinSkinType 1 diabetesCross-Over StudiesInsulin Lisprobusiness.industryInsulinMicrocirculationBlood flowmedicine.diseasePostprandial PeriodAcetylcholinePostprandialEndocrinologyDiabetes Mellitus Type 1Regular insulinFemaleEndothelium VascularbusinessBlood Flow Velocitymedicine.drugJournal of diabetes and its complications
researchProduct

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.

2003

Pharmacokinetic and pharmacodynamic profiles of the rapid-acting insulin analogues lispro and aspart were compared in a randomized, double-blind crossover study of 20 fasting healthy men following a single subcutaneous injection. Either insulin lispro or aspart, 0.05 U/kg-body-weight, was injected subcutaneously and followed by determination of 5-h profiles of plasma glucose, serum C-peptide and insulin concentrations. Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l). For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRadioimmunoassayInsulin aspartSubcutaneous injectionEndocrinologyPharmacokineticsDouble-Blind MethodDiabetes mellitusInternal medicineInternal MedicinemedicineInsulin lisproHumansHypoglycemic AgentsInsulinInsulin AspartCross-Over StudiesInsulin LisproC-Peptidebusiness.industryInsulindigestive oral and skin physiologynutritional and metabolic diseasesGeneral Medicinemedicine.diseaseCrossover studyEndocrinologyPharmacodynamicsbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.

2008

BACKGROUND: Insulin glargine is a once-daily basal insulin analog with prolonged duration of action and absence of an evident peak. Glargine is associated with reduced frequency of hypoglycemic episodes (mostly nocturnal) as well as effective glycemic control. Maintenance of good metabolic control before conception and throughout pregnancy is essential to lower the risk of fetal malformations. Glargine might be a valuable alternative in the management of pregnancies complicated by diabetes mellitus. However, because its clinical utility has not been established, the use of glargine is not currently recommended during pregnancy. OBJECTIVE: The aim of this study was to retrospectively evaluat…

AdultBlood Glucosemedicine.medical_specialtyInsulin IsophanePregnancy in DiabeticsInsulin GlargineSettore MED/13 - EndocrinologiaInsulin aspartPregnancyDiabetes mellitusInternal medicinemedicineOutpatient clinicInsulin lisproHumansHypoglycemic AgentsInsulinPharmacology (medical)Body Weights and MeasuresFemurInsulin AspartGlycemicRetrospective StudiesPharmacologyGlycated HemoglobinType 1 diabetesPregnancyInsulin LisproInsulin glarginebusiness.industryglargine type 1 diabetesPregnancy Outcomemedicine.diseaseInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 1Case-Control StudiesFemalebusinessmedicine.drugClinical therapeutics
researchProduct